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Abstract
The SNTA1-encoded α1-syntrophin (SNTA1) missense mutation, p.A257G, causes long QT
syndrome (LQTS) by pathogenic accentuation of Nav1.5’s sodium current (INa). Subsequently, we
found p.A257G in combination with the SNTA1 polymorphism, p.P74L in 4 victims of sudden
infant death syndrome (SIDS) as well as in 3 adult controls. We hypothesized that p.P74L-SNTA1
could functionally modify the pathogenic phenotype of p.A257G-SNTA1, thus explaining its
occurrence in non-LQTS populations. The SNTA1 variants p.P74L, p.A257G, and the
combination variant p.P74L/p.A257G were engineered using PCR-based overlap-extension and
were co-expressed heterologously with SCN5A in HEK293 cells. INa was recorded using the
whole-cell method. Compared to wild-type (WT), the significant increase in peak INa and window
current found with p.A257G was reversed by the intragenic variant p.P74L (p.P74L/p.A257G).
These results report for the first time the intragenic rescue of an LQT-associated SNTA1 mutation
when found in combination with the SNTA1 polymorphism p.P74L, suggesting an ever-increasing
picture of complexity in terms of genetic risk stratification for arrhythmia.
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Introduction
Long QT syndrome (LQTS) is a heritable cardiac arrhythmia affecting approximately 1 in
2500 individuals.1 LQTS is characterized by a prolongation of the QT interval on the ECG,
and is most often manifested clinically as syncope, seizures, or sudden death due to its
trademark arrhythmia torsades de pointes.2 Thus far, 12 genes have been implicated in
LQTS, with approximately 75%3,4 of LQTS caused by mutations in the KCNQ1-encoded
potassium channel (LQT1),5 KCNH2-encoded potassium channel (LQT2)6 or the SCN5A-
encoded sodium channel (LQT3).7 Recent studies have also suggested that up to 10% of
sudden infant death syndrome (SIDS) may be due to early manifestations of LQTS or other
cardiac channelopathies during the first year of life.8-16
Recently, we discovered that the LQT3-associated cardiac sodium channel, Nav1.5, is
connected by the SNTA1-encoded scaffolding protein (α1-syntrophin, SNTA1) to neuronal
nitric oxide synthase (nNOS) and the cardiac iso-form of the plasma membrane Ca-ATPase
(PMCA4b) in a complex in cardiomyocytes. Moreover, we implicated SNTA1 as a novel
susceptibility gene for both LQTS17 and SIDS16 whereby the SNTA1 mutant disrupted
binding with PMCA4b, released inhibition of nNOS, and accentuated both peak and late INa
via Snitrosylation of the cardiac sodium channel. In addition we also have reported a new
LQTS-associated SNTA1 missense mutation (c.770C > G, p.A257G) which precipitated a
marked increase in peak INa and altered Nav1.5 channel kinetics in both HEK293 cells and
cardiomyocytes through direct interaction of mutant SNTA1 with SCN5A.18 All these
findings suggest that SNTA1 is a crucial Nav1.5 channel interacting protein (ChIP) involved
in maintaining the normal function of the cardiac sodium channel.
The p.A257G-SNTA1 mutation was identified initially in a separate publication by our
group in 3 unrelated LQTS probands out of 39 LQTS patients but absent in 200 ethnic-
matched control individuals.18 This study demonstrated that p.A257G-SNTA1 can
functionally interact with SCN5A in HEK293 cells without requiring nNOS or PMCA4b.
Lastly, in a population-based cohort of 292 SIDS cases, we reported in 4 Caucasian SIDS
victims the presence of p.A257G in combination with another single-nucleotide alteration (c.
221C > T) that results in the amino acid substitution p.P74L.16 Interestingly, the combined
variant of p.P74L/p.A257G was also found in 3 out of 400 additional adult controls not
included in the initial study. None of the SIDS cases or the 400 adult controls was positive
for either p.P74L- or p.A257G-SNTA1 in isolation.16
Given the following data points: i) that p.A257G-SNTA1 in isolation is an LQTS-associated
mutation with abnormal biophysical characteristics,18 ii) that p.A257G-SNTA1 was
identified in an ostensibly healthy population only in the presence of p.P74L-SNTA1, and
iii) that in an at-risk population of SIDS victims p.A257G-SNTA1 occurred multiple times,
but only in the presence of p.P74L-SNTA1, we hypothesized that p.P74L may rescue the
abnormal phenotype caused by p.A257G in isolation, therefore explaining its occurrence
both in the general population compared to the LQT-associated single p.A257G missense
mutation in isolation, as well as its occurrence at a higher frequency (>1%) in SIDS than
would be expected were the combination p.P74L/p.A257G-SNTA1 variant to be a highly
pathogenic variant.
Materials and Methods
Plasmid constructions of mammalian expression vectors
The cDNA (GenBank Accession no. NM_003098) of wild type (WT) human SNTA1 gene
was subcloned into the pIRES2EGFP plasmid vector (Clontech Laboratories, Palo Alto,
California, USA). The p.P74L-, p.A257G-, and combination p.P74L/p.A257G-SNTA1
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variants were incorporated into WT-SNTA1 using the PCR-based overlap-extension method
as previously reported.16,17 All clones were sequenced to confirm integrity and to ensure the
presence of the introduced variants and the absence of other substitutions caused by PCR.
Mammalian cell transfection
The WT or mutant SNTA1 in pIRES2EGFP vector was transiently co-transfected with
expression vectors containing SCN5A (hNav1.5, Genbank accession no. AB158469) in the
dominant splice variant background Q1077del into HEK293 cells with FuGENE6 reagent
(Roche Diagnostics, Indianapolis, Indiana, USA) according to manufacturer’s instructions.
Cells were selected for electrophysiologic studies based on comparable levels of GFP
fluorescence, and WT and mutant were transfected on the same day.
Electrophysiological measurements
Macroscopic voltage-gated INa was measured 48 hours after transfection with the standard
whole-cell patch clamp method at 21°C to 23°C in the HEK293 cells. The extracellular
(bath) solution contained the following (in mM): NaCl 140, KCl 4, CaCl2 1.8, MgCl2 0.75
and HEPES 5 and was adjusted to pH 7.4 with NaOH. The intracellular (pipette) solution
contained the following (in mM): CsF 120, CsCl2 20, EGTA 2, NaCl 5, and HEPES 5 and
was adjusted to pH 7.4 with CsOH. Microelectrodes were manufactured from borosilicate
glass using a puller (P-87, Sutter Instrument Co, Novato, California, USA) and were heat
polished with a microforge (MF-83, Narishige, Tokyo, Japan). The resistances of
microelectrodes ranged from 1.0 to 2.0 MΩ. Voltage clamp data were generated with
pClamp software 10.2 and an Axopatch 200B amplifier (Axon Instruments, Foster City,
California, USA) with series-resistance compensation. Membrane current data were
digitalized at 100 kHz, low-pass filtered at 5 kHz, and then normalized to membrane
capacitance.
Persistent or late INa was measured as the mean between 600 and 700 ms after the initiation
of the depolarization from -140 mV to -20 mV for 750 ms after passive leak subtraction as
previously described.13,16,17,19 Time course of recovery from inactivation was analyzed by
fitting data with a two-exponential (exp) function: normalized INa (t) = Af [1 - exp(-t/τf)] +
As [1 - exp(-t/τs)], where t is time, Af and As are fractional amplitudes of fast and slow
components, respectively, and τf and τs are fast and slow time constant, respectively. Decay
rates and amplitude component were measured from the trace beginning after peak INa at
90% of peak INa to 24 ms and fitted with a sum of exponentials(exp): INa (t) = 1 - [Af exp(-t/
τf) + As exp(-t/τs)] + offset, where t is time, and Af and As are fractional amplitudes of fast
and slow components, respectively. The other standard voltage clamp protocols are
presented with the data and data were measured and analyzed as described
previously13,16,17,19 and with additional details provided in the figure legends.
Quantification of window currents was performed by calculating the area under the
activation/inactivation curves per cell, and averaging cells for each group to assess for
statistical differences.
Statistical analysis
All data points are reported as the mean value and the standard error of the mean (SEM).
Determinations of statistical significance were performed using a Student t-test for
comparisons of two means or using analysis of variance (ANOVA) for comparisons of
multiple groups. Statistical significance was determined by a value of P < 0.05.
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Results
HEK293 cells were transiently transfected with Nav1.5 and either WT-SNTA1,
p.P74LSNTA1, p.A257G-SNTA1, or p.P74L/p.A257GSNTA1. Compared with WT-
SNTA1, p.P74LSNTA1 alone, and p.P74L/p.A257G-SNTA1, p.A257G-SNTA1
significantly increased peak INa density as previously reported (P < 0.05). Neither p.P74L-
SNTA1 alone nor the double variant p.P74L/p.A257G-SNTA1 had a significant difference
in peak INa amplitude compared to WT (Figure 1A; Table 1). These data suggest that the
abnormal increased peak INa caused by p.A257G is negatively regulated intragenically by
p.P74L back to approximately WT level.
To assess the effects of these mutants on late INa, we measured the level of late INa after leak
subtraction as a percentage of peak INa elicited by prolonged depolarization. However,
p.P74L, p.A257G and p.P74L/p.A257G showed similar percentages of late INa as WT-
SNTA1 (Table 1), suggesting that the direct interaction of these SNTA1 mutants with
Nav1.5 does not affect late INa.
We analyzed the kinetic parameters of activation and inactivation for these 3 SNTA1
variants and compared these data with WT-SNTA1. The p.P74L-SNTA1 variant showed no
significant difference in either activation or inactivation compared with WT-SNTA1. As
previously reported, the LQTS-associated p.A257G-SNTA1 missense mutation caused a
statistically significant hyperpolarizing shift in activation and had comparable inactivation
parameters to WT, thus increasing the overlap of the activation and inactivation curves, and
resulting in increased window current. However, for p.P74L/p.A257G-SNTA1 both
activation and inactivation were significantly shifted toward the hyperpolarizing direction
and reversed the increased channel availability caused by p.A257G, significantly decreasing
the window current from p.A257G-SNTA1 alone (Figure 1B-1F; Table 1).
The recovery time from fast inactivation was analyzed by fitting the data with a double-
exponential equation. p.A257G-SNTA1 showed an increase in the fast component of the
time constant τf (1.99 ± 0.16 ms, n = 20) compared with WT (1.63 ± 0.10 ms, n = 17; P =
0.04) as previously reported,18 but there was no significant difference in time constant (τf,
τs) and fractional amplitudes between WT, p.P74L, and p.P74L/p.A257G (data not shown).
Due to the shift of activation parameters, we analyzed the decay of the peak INa with 2-
exponential fits of decay phase of macroscopic INa. There was no difference in either time
constants (τf, τs) or fractional amplitudes of 2 components observed in all mutants.
Discussion
As previously reported, four cases out of a population-based cohort of 292 SIDS victims and
three subjects out of 400 control subjects were heterozygous for the combined variants
p.P74L-SNTA1 and p.A257G-SNTA1 in α1-syntrophin.16,18 Given the frequency of these
two variants, and that neither variant was found in isolation in the SIDS cohort nor in the
400 reported adult controls, it is extremely likely that they are located on the same allele.
Conversely, the p.A257G mutation without the p.P74L variant was found in isolation in
three patients with LQTS.18 No other putative cardiac channelopathic gene mutations had
been identified previously in these 4 SIDS victims.11,13-15,20 Because of the anonymized
nature of the SIDS study, determination of genetic variants as transmitted or de novo was
not possible.
The novel finding in this study is that the intragenic p.P74L-SNTA1 variant distinctively
abolished the increased peak INa caused by the LQTS-associated p.A257G-SNTA1 missense
mutation, thus reconciling the pro-arrhythmic nature of the mutation p.A257G-SNTA1 with
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its discovery in a presumably healthy population as well as in our SIDS cohort at a > 1%
frequency. To the best of our knowledge, this is the first report elucidating the functional
interaction of a LQTS-associated SNTA1 mutation with an intragenic SNTA1
polymorphism.
Our group recently identified that the LQTS-associated SNTA1 missense mutation p.A257G
markedly accentuated peak INa through the interaction of SNTA1 with Nav1.5 independent
of the nNOS-PMCA4b nitrosylation pathway.18, The present investigation showed that the
intragenic combination of p.P74L-SNTA1 and p.A257G-SNTA1 significantly reverses the
increased peak INa associated with p.A257GSNTA1 alone, and exerts an additional channel
kinetic modification (negative shift for inactivation) on Nav1.5. The biophysical phenotype
of normalized peak INa in p.P74L/p.A257G suggests that p.P74L plays a protective role, and
could account for the persistence of p.P74L/p.A257G in the general population. Meanwhile,
it also suggests that like the vast majority of SIDS cases, the pathogenic cause of the 4 SIDS
cases with this combined variant remains elusive and the p.P74L/p.A257G combined variant
did not contribute to their demise.
Notably, the two variants occurred on either side of the PDZ domain of SNTA1 (Figure 2).
Specifically, p.P74L localizes to the first pleckstrin homology 1 (PH1) domain (amino acids
1-86) while p.A257G localizes to the second PH1 domain (amino acids 171-269). At the
sarcolemma of the skeletal and cardiac muscles, SNTA1, the most abundant syntrophin
isoform in heart muscle,21,22 was shown to interact through its PDZ domain with many
transmembrane channels such as sodium channels SkM1, SkM2, and Nav1.5,23,24 potassium
channel Kir4.1,25 and transient receptor potential channels (TRPC).26 More recently, the N-
terminal part of SNTA1 containing the PDZ domain was confirmed to be necessary for
SNTA1 to normally regulate TRPC1 channel27 as well as to interact with the α1D-adrenergic
receptor.28 Given its prominent modification of the biophysical phenotype, this interesting
combined variation in the PH1 domain surrounding the PDZ domain provides us at least two
questions to be further addressed: i) Is the PH1 domain necessary for a functional interaction
between SNTA1 and Nav1.5? ii) Do these SNTA1 variants also have special effects on other
proteins with PDZ binding sites in the Nav1.5 macromolecular complex in vivo?
In this study, we report for the first time an instance of intragenic complementation
modulating the pathogenic phenotype of a mutation in a channelopathy-susceptibility gene.
In particular, the functional characterization of the combination variant p.P74L/p.A257G-
SNTA1 found in both SIDS and controls demonstrates an intragenic interaction of these two
single nucleotide changes in SNTA1 by which the p.A257G mutant phenotype is abolished.
To our knowledge, that an arrhythmia-associated mutation, namely p.A257G-SNTA1, in a
ChIP is rescued by another intragenic variant has not been previously reported. However,
this is certainly not the first report of this biological phenomenon. A common example in the
cancer literature is the tumor suppressor p53, often mutated in cancer cells, in which the
intragenic polymorphism R72P affects multiple p53 antitumor properties as well as drug
response in a p53 mutation-dependent manner.29-31
To what extent this interaction is important in a more native cardiac environment as opposed
to a heterologous expression system will need to be explored. However, it should be
emphasized that the p.A257G-SNTA1 mutant phenotype appears to be nitrosylation-
independent, since pathogenic changes were noted in a heterologous system without the
presence of nNOS or PMCA4b, consistent with previous data.18 These changes were
abrogated in the presence of p.P74L without recapitulating the nitrosylation complex.
Indeed, these findings present a mounting challenge in terms of properly recapitulating the
proper sodium channel macromolecular complex for performing such studies. Given the
increasing evidence of the interplay between genetic variation among various subunits,
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caution must be exercised in properly interpreting such data not only from heterologous
systems but indeed from any system that attempts to artificially recapitulate a mutant
phenotype. An additional limitation to the present study is the lack of high-integrity RNA
material to demonstrate the existence of p.P74L and p.A257G on the same SNTA1 allele.
However, neither variant was identified in isolation in either our SIDS cohort or the controls
examined. In addition, p.A257G was identified in the previous study in isolation only in
LQTS-positive individuals, and p.P74L was not detected in those individuals. Thus it is
extremely unlikely in control populations that p.A257G would exist in isolation rather than
in linkage disequilibrium with a protective variant. Therefore, the current data support the
previously argued pathogenic role of p.A257GSNTA1 when found in isolation without the
accompanying polymorphism p.P74L-SNTA1.
In conclusion, this study highlights the complicated mechanism by which SNTA1 regulates
Nav1.5, and emphasizes the potential role of genetic variation in Nav1.5 macromolecular
complex-related disorders, as well as the increasingly complicated role that the individual
genetic fingerprint plays in modulating the penetrance/expressivity of disease-associated
mutations.
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Figure 1.
Co-transfection of SNTA1 with SCN5A. A) Representative whole-cell current traces of
HEK293 cells co-expressing WT or mutant SNTA1 and SCN5A, showing increased peak
INa for p.A257G-SNTA1. The currents were recorded at membrane potentials between -120
to +60 mV in 10-mV increments from a holding potential of -140 mV as depicted in the
protocol inset. B) Activation was measured using this protocol: currents were elicited by
step depolarization for 24 ms to different potentials between −120 mV to 60 mV from a
holding potential of −140 mV. The curves were fit with a Boltzmann function where GNa =
[1+exp (V1/2 - V) / K]-1, where V1/2 and k are the midpoint and slope factor, respectively.
G/GNa = INa (norm)/ (V - Vrev) where Vrev is the reversal potential and V is the membrane
potential. p.A257G- and p.P74L/p.A257G-SNTA1 mutations caused a statistically
significant hyperpolarizing shift in steady-state activation by 2.1-2.7 mV. C) Steady-state
availability from inactivation was measured using the protocol shown in the inset and was
determined by fitting the data to the Boltzmann function: INa = INa-Max [1+exp (Vc - V1/2) /
K]-1, where V1/2 and k are the midpoint and the slope factor, respectively, and Vc is the
membrane potential. p.P74L/p.A257G-SNTA1 mutation had a statistically significant
hyperpolarizing shift in steady-state inactivation by 2.6 mV. D) The peak current activation
data are replotted as a conductance (G) curve with steady-state inactivation relationships to
show p.A257G increases the overlap of these relationships (window current). E) The peak
current activation data are replotted as a conductance (G) curve with steady-state
inactivation relationships to show p.P74L/p.A257G reverses the increased overlap of these
relationships. Circles indicate activation, whereas squares indicate inactivation. Lines
represent fits to Boltzmann equations with parameters of the fit and n numbers in Table 1. F)
shows an increase in quantified window current area for p.A257G-SNTA1 compared with
both WT-SNTA1 as well as p.P74L-p.A257G-SNTA1. *P<0.05 compared with WT and
p.P74L/p.A257G. The experiment numbers are shown within each bar.
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Figure 2.
Localization of SNTA1 variants. Illustrated is the linear topology for SNTA1 with variant
localization.
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